바로가기메뉴

본문 바로가기 주메뉴 바로가기

ACOMS+ 및 학술지 리포지터리 설명회

  • 한국과학기술정보연구원(KISTI) 서울분원 대회의실(별관 3층)
  • 2024년 07월 03일(수) 13:30
사전등록 바로가기
 

logo

메뉴
search

ISSN : 0376-4672

논문 상세

다음
논문 투고

61권 7호

약물관련 골괴사(MRONJ) 치료권고안, 무엇이 달라졌나?

Position Papers on MRONJ(Medication related osteonecrosis of the jaw), What has changed?

권대근 (경북대학교)
대한치과의사협회지 / The Journal of the Korean Dental Association, (P)0376-4672; (E)2713-7961
2023, v.61 no.7, pp.444-459
https://doi.org/10.22974/jkda.2023.61.7.001
권대근. (2023). 약물관련 골괴사(MRONJ) 치료권고안, 무엇이 달라졌나?. 대한치과의사협회지, 61(7), 444-459, https://doi.org/10.22974/jkda.2023.61.7.001

Abstract

Antiresorptives, such as bisphosphonate, denosumab, are widely prescribed drugs for the treatment of osteoporosis, os teopenia, malignant bone metastases, multiple myeloma and Paget`s disease. They have therapeutic efficacy for controlling bone pain and reducing skeletal related events including the pathologic fractures. However, it was reported that the develop ment of osteonecrosis of the jaw(ONJ) could be related to antiresorptive treatments. It was first defined as Bisphosphonate related osteonecrosis of the jaw in 2007 American Association of Oral and Maxillofacial Surgeons(AAOMS) position pa per. This was changed to Medication-related osteonecrosis of the jaw(MRONJ) in the AAOMS position paper 2014. This position paper was updated recently in May 2022 and contains revisions to disease definition and management strategies at “AAOMS position paper on MRONJ-2022 update”. The important changes in clinical implications are as follows; 1) In the definition, immune modulators (such as Romosozumab) were included with potential medications related with osteo necrosis of the jaw (ONJ), 2) Operative therapy was included for all stages (1, 2 and 3) in treatment strategies, 3) Formerly mentioned drug holiday before surgical procedure to prevent MRONJ was not identified in 2022 AAOMS position paper. Most of the statements in AAOMS 2022 position paper were based on strict literature reviews and changes were made if there is little evidence to suggest the specific diagnosis or therapeutic options. Understanding the changes compared to the previous position papers is important in selecting adequate treatment strategies for MRONJ.

keywords
MRONJ, bisphosphonate, denosumab, antiresorptive agent, position paper

참고문헌

1.

1. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws AAoO, Maxillofacial S. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65(3):369-76.

2.

2. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014;72(10):1938-56.

3.

3. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3-23.

4.

4. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479-91.

5.

5. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009;67(5 Suppl):2-12.

6.

6. Otto S, Marx RE, Troltzsch M, Ristow O, Ziebart T, Al-Nawas B, et al. Comments on "diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus". J Bone Miner Res. 2015;30(6):1113-5.

7.

7. Japanese Allied Committee on Osteonecrosis of the J, Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, et al. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab. 2017;35(1):6-19.

8.

8. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons'Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg. 2022;80(5):920-43.

9.

9. UK_Chemotherapy_Board. Medication-related osteonecrosis of the jaw, Guidance for the oncology multidisciplinary team. https://wwwrcplondonacuk/guidelines-policy/medicationrelated-osteonecrosis-jaw-guidance-oncology-multidisciplinary-team. 2019;Accessed on 2023-03-14.

10.

10. Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(25):2270-90.

11.

11. Campisi G, Mauceri R, Bertoldo F, Bettini G, Biasotto M, Colella G, et al. Medication-Related Osteonecrosis of Jaws (MRONJ)Prevention and Diagnosis: Italian Consensus Update 2020. Int J Environ Res Public Health. 2020;17(16).

12.

12. Kim JW, Kwak MK, Han JJ, Lee ST, Kim HY, Kim SH, et al. Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone Metab. 2021;28(4):279-96.

13.

13. US_FDA. Background document for meeting of advisory committee for reproductive health drugs and drug safety and risk management advisory committee. http://wwwfdagov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM270958pdf.

14.

14. Ishimaru M, Ono S, Morita K, Matsui H, Hagiwara Y, Yasunaga H. Prevalence, Incidence Rate, and Risk Factors of Medication-Related Osteonecrosis of the Jaw in Patients With Osteoporosis and Cancer: A Nationwide Population-Based Study in Japan. J Oral Maxillofac Surg. 2022;80(4):714-27.

15.

15. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972-80.

16.

16. Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res. 2018;33(2):190-8.

17.

17. Dennison EM, Cooper C, Kanis JA, Bruyere O, Silverman S, McCloskey E, et al. Fracture risk following intermission of osteoporosis therapy. Osteoporos Int. 2019;30(9):1733-43.

18.

18. The_Scottish_Dental_Clinical_Effectiveness_Programme(SDCEP). Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw: Dental Clinical Guidance https://wwwsdceporguk/media/m0ko0gng/sdcep-oral-health-management-of-patients-at-risk-ofmronj-guidance-fullpdf. 2017;Accessed on 2023-03-14.

19.

19. Campisi G, Mauceri R, Bertoldo F, Fusco V, Bedogni A. A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis. Head Face Med. 2021;17(1):25.

20.

20. Salgueiro M, Stribos M, Zhang LF, Stevens M, Awad ME, Elsalanty M. Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): a retrospective clinical study. EPMA J. 2019;10(1):21-9.

21.

21. Hasegawa T, Ueda N, Yamada SI, Kato S, Iwata E, Hayashida S, et al. Denosumab-related osteonecrosis of the jaw after tooth extraction and the effects of a short drug holiday in cancer patients: a multicenter retrospective study. Osteoporos Int. 2021;32(11):2323-33.

22.

22. Hasegawa T, Hayashida S, Kondo E, Takeda Y, Miyamoto H, Kawaoka Y, et al. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study. Osteoporos Int. 2019;30(1):231-9.

23.

23. Hasegawa T, Kawakita A, Ueda N, Funahara R, Tachibana A, Kobayashi M, et al. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ? Osteoporos Int. 2017;28(8):2465-73.

24.

24. Omori K, Otsuru M, Morishita K, Hayashida S, Suyama K, Naruse T, et al. Ineffectiveness of Antiresorptive Agent Drug Holidays in Osteoporosis Patients for Treatment of Medication-Related Osteonecrosis of the Jaw: Consideration from Immunohistological Observation of Osteoclast Suppression and Treatment Outcomes. Int J Environ Res Public Health. 2022;19(17).

25.

25. Morishita K, Soutome S, Otsuru M, Hayashida S, Murata M, Sasaki M, et al. Relationship between drug holiday of the antiresorptive agents and surgical outcome of medication-related osteonecrosis of the jaw in osteoporosis patients. Sci Rep. 2022;12(1):11545.

26.

26. Hayashida S, Yanamoto S, Fujita S, Hasegawa T, Komori T, Kojima Y, et al. Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw. J Bone Miner Metab. 2020;38(1):126-34.

27.

27. Malan J, Ettinger K, Naumann E, Beirne OR. The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114(6):671-6.

28.

28. O'Halloran M, Boyd NM, Smith A. Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases. Aust Dent J. 2014;59(4):516-9.

29.

29. de Molon RS, Shimamoto H, Bezouglaia O, Pirih FQ, Dry SM, Kostenuik P, et al. OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice. J Bone Miner Res. 2015;30(9):1627-40.

30.

30. Owosho AA, Blanchard A, Levi L, Kadempour A, Rosenberg H, Yom SK, et al. Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients. J Craniomaxillofac Surg. 2016;44(3):265-70.

31.

31. Hoefert S, Yuan A, Munz A, Grimm M, Elayouti A, Reinert S. Clinical course and therapeutic outcomes of operatively and non-operatively managed patients with denosumab-related osteonecrosis of the jaw (DRONJ). J Craniomaxillofac Surg. 2017;45(4):570-8.

32.

32. Aljohani S, Gaudin R, Weiser J, Troltzsch M, Ehrenfeld M, Kaeppler G, et al. Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series. J Craniomaxillofac Surg. 2018;46(9):1515-25.

33.

33. Yoshida T, Watanabe T, Akizuki S, Okishio Y, Fujikawa N, Mori A, et al. Adverse events caused by the discontinuation of antiresorptive agents during treatment for anti-resorptive agentrelated osteonecrosis of the jaw: A single-center cohort study. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology. 2021;33(2):115-9.

34.

34. Kim KM, Rhee Y, Kwon YD, Kwon TG, Lee JK, Kim DY. Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone Metab. 2015;22(4):151-65.

logo

논문 투고
OA 정책